Search Within

Population Sciences Research Program

  1. "Breast Medicine Service"
  2. "Psychiatry and Behavioral Sciences, Department of"
  3. "Teresa Gilewski"
Formats
  1. Journal Article (20)
  2. Meeting Abstract (12)
Groups
  1. Behavioral Sciences Service (32)
  2. Breast Medicine Service (32)
  3. Department of Medicine (32)
  4. Psychiatry and Behavioral Sciences, Department of (32)
  5. Solid Tumor Oncology Division (32)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (30)

More Groups

People
  1. Teresa Gilewski (32)
  2. Larry Norton (28)
  3. Clifford Hudis (20)
  4. Gabriella D'Andrea-Carlino (16)
  5. Diana Lake (14)
  6. Mark Robson (14)

More People

Years
  1. 2015 (3)
  2. 2014 (1)
  3. 2013 (1)
  4. 2012 (1)
  5. 2011 (2)
  6. 2009 (1)

More Years

Publications
  1. Cancer Research (6)
  2. Journal of Clinical Oncology (6)
  3. Clinical Cancer Research (5)
  4. American Journal of Human Genetics (3)
  5. Breast Cancer Research and Treatment (3)
  6. Clinical Breast Cancer (2)

More Publications

Publishers
  1. American Association for Cancer Research (11)
  2. American Society of Clinical Oncology (6)
  3. Cell Press (3)
  4. Springer (3)
  5. American Medical Association (2)
  6. Elsevier Inc. (2)

More Publishers

Results (32)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Hamilton, N.; Caravella, B. A.; Zamora, S.; Dang, C.; Gilewski, T.; Traina, T.; Comen, E.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Caravella, B. A.; Datko, F. M.; Zamora, S.; Comen, E.; Gilewski, T.; Sugarman, S. M.; D'Andrea, G.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
    Journal Article

    Dang, C.; Iyengar, N.; Datko, F.; D'Andrea, G.; Theodoulou, M.; Dickler, M.; Goldfarb, S.; Lake, D.; Fasano, J.; Fornier, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with Metastatic breast cancer
    Journal Article

    Jhaveri, K.; Chandarlapaty, S.; Lake, D.; Gilewski, T.; Robson, M.; Goldfarb, S.; Drullinsky, P.; Sugarman, S.; Wasserheit Leiblich, C.; Fasano, J.; more...
    Clinical Breast Cancer (2014)

    Fulltext@MSK | Save
  • An exploratory analysis of the role of dasatinib in preventing progression of disease in bone in patients with metastatic breast cancer
    Meeting Abstract

    Cadoo, K. A.; Morris, P. G.; Lake, D. E.; D'Andrea, G. M.; Dickler, M. N.; Gilewski, T. A.; Dang, C. T.; McArthur, H. L.; Bromberg, J. F.; Goldfarb, S. B.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer
    Meeting Abstract

    Datko, F.; D'Andrea, G.; Dickler, M.; Theodoulou, M.; Goldfarb, S.; Lake, D.; Fornier, M.; Modi, S.; Sklarin, N.; Comen, E.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save
  • A pilot study of vaccination with sialyl Lewis(a) (sLe(a))-keyhole limpet hemocyanin (KLH) conjugate plus the immunologic adjuvant QS-21 in metastatic breast cancer patients (pts)
    Meeting Abstract

    Diab, A.; Ragupathi, G.; Scholz, W. W.; Panageas, K.; Hudis, C.; Livingston, P. O.; Gilewski, T.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A feasibility study of bevacizumab plus dose-dense doxorubicin- cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer
    Journal Article

    Mcarthur, H. L.; Rugo, H.; Nulsen, B.; Hawks, L.; Grothusen, J.; Melisko, M.; Moasser, M.; Paulson, M.; Traina, T.; Patil, S.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: Updated results
    Meeting Abstract

    Dang, C.; Lin, N.; Moy, B.; Come, S.; Lake, D.; Theodoulou, M.; Troso-Sandoval, T.; Dickler, M.; Gorsky, M.; D'Andrea, G.; more...
    Cancer Research (2009)

    Fulltext@MSK | Save
  • A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer
    Journal Article

    Dickler, M. N.; Rugo, H. S.; Eberle, C.; Brogi, E.; Caravelli, J.; Panageas, K. S.; Boyd, J.; Yeh, B.; Lake, D. E.; Dang, C.; more...
    Clinical Cancer Research (2008)

    Fulltext@MSK | Save